Agilent Technologies Real-Time, Quantitative Cell Analysis, xCELLigence
Agilent Technologies Real-Time, Quantitative Cell Analysis, xCELLigence — Cell analysis.
The xCELLigence RTCA eSight is a real-time, quantitative cell analysis instrument combining impedance-based monitoring with live-cell imaging in a 48-well format. It is the imaging-capable variant of the RTCA series, distinguished from the DP, SP, MP, and HT siblings by integrated microscopy. It serves label-free, kinetic assays such as antibody internalization and immunotherapy profiling.
Full specifications
| Throughput | 48 wells |
| Cell line mfr | 474 |
| Culture medium mfr | Hybri-Care Care |
| Medium supplement mfr | 10 % pen/strep |
| Labeling dye-to-protein ratio mfr | 3.9 |
| Isotype control mfr | 1 |
| Secondary detection antibody mfr | 5 E |
| Dye activation pH mfr | 4.7 pH |
| MCF7 mfr | DMEM DMEM |
| HCC1954 mfr | 1640 |
| SKBR3 mfr | 1640 |
| BT474 mfr | Hybri-Care Care |
| CO2 concentration mfr | 5 |
| antibody dilution concentration mfr | 1 mg/mL |
| labeling buffer pH mfr | 8.3 |
| sodium bicarbonate concentration mfr | 7.5 |
| molar excess of dye mfr | 20 fold |
| labeling incubation time mfr | one hour hour |
| short-term storage duration mfr | 24 hours |
| continuous measurement duration mfr | 72 hours |
| endosome pH mfr | 6.3 |
| lysosome pH mfr | 4.7 |
| trastuzumab-CypHer5E D/P mfr | 3.9 |
| Isotype IgG1-CypHer5E D/P mfr | 3.4 |
| Fab-CypHer5E D/P mfr | 10.5 |
| trastuzumab-CypHer5E concentration mfr | 2 μg/mL |
| imaging interval mfr | one-hour intervals intervals |
| imaging duration mfr | 48 hours |
| indirect labeling EC50 mfr | 124.00 ng/mL |
| trastuzumab EC50 mfr | 135.5 ng/mL |
| Oncolytic viruses mfr | 40 |
| Selected publications mfr | 50 |
| T Cell-mediated cytolysis mfr | 44 |
| biosensor surface coverage mfr | 75 |
| 96-well plate read time mfr | 15 seconds |
| independent plates mfr | six plates plates |
| DP format mfr | 3 wells |
| SP format mfr | 1 wells |
| MP format mfr | 6 wells |
| HT format mfr | 1 wells |
| eSight impedance format mfr | 3 wells |
| eSight imaging format mfr | 5 wells |
| SP maximum throughput mfr | 96 wells |
| MP maximum throughput mfr | 576 wells |
| eSight impedance throughput mfr | 288 wells |
| SKOV3 mfr | 5 A |
| Liquid tumor killing assays mfr | 48 |
Description
Construction and series positioning
The xCELLigence RTCA eSight is a 48-well real-time cell analyzer that integrates impedance measurement with live-cell imaging. Within the RTCA series, the eSight is the only variant with microscopy; the DP, SP, MP, and HT siblings provide impedance-only detection at different plate-handling scales. The eSight is therefore selected when kinetic impedance data must be correlated with visual events in the same well.
Measurement behavior
Operation is label-free: cells are monitored by impedance across electrodes in each well, and the eSight adds image capture for the same wells. The 48-well throughput supports parallel conditions. Application notes describe use with CypHer5E-labeled trastuzumab and secondary CypHer5E-Fab conjugates in HER2-positive lines (MCF7, SKBR3, BT474) for internalization assays, and with HepG2 cells for water cytotoxicity screening. No curve points or dynamic ranges are provided in the verified facts, so no rate or sensitivity figures are stated here.
Control and operation
No electrical, interface, environmental, or compliance specifications were supplied for this model. Installation, connection, and control details are not available from the verified facts; the document digests list application scope only and contain no actionable engineering facts. Configuration and ordering information should be confirmed against the current Agilent RTCA eSight specification.
Integration & Operating Notes
The eSight variant pairs impedance traces with image capture, so assay design must reserve well space and timing for both readouts. The verified facts do not specify acquisition rates, camera settings, or software controls; these must be taken from the instrument manual.
CypHer5E-NHS-ester dyes, labeled antibodies, electrode plates, and cell culture reagents are assay-specific and supplied separately. The verified facts contain no maintenance interval, error-code, or accessory list for this model; service schedule must be obtained from Agilent documentation.
Selection & Integration Q&A
Choose the eSight when impedance kinetics must be correlated with live-cell images in the same 48-well plate, as in antibody internalization studies. The DP, SP, MP, and HT siblings provide impedance-only detection at different plate-handling scales; select them when imaging is not required.
The assay requires the dedicated 48-well electrode plates, CypHer5E-NHS-ester labeling dye, and target antibodies such as trastuzumab or CypHer5E-Fab conjugates. HER2-positive lines MCF7, SKBR3, and BT474 are demonstrated. The verified facts do not list a controller or power supply specification.
The verified facts contain no environmental, electrical, or duty-cycle specifications for this model. Operating temperature, humidity, and continuous-run limits must be confirmed from the Agilent RTCA eSight instrument manual before installation planning.
Electrode plates, CypHer5E labeling reagents, antibodies, and cell culture media are consumables not included with the instrument. The verified facts give no service interval or error-code list; maintenance scheduling must come from Agilent service documentation.